




INNOVATION AND COMMERCIALIZATION

NOVEMBER 2020



2020 IMPACT REPORT



**2020 Technology Transfer Impact Report**

Despite the challenges of 2020, the OHSU Technology Transfer team is honored to highlight many of the successes and positive impacts made on society over the past year in our annual 2020 Impact Report. [Read more.](#)



### **Phase 0 program (SBIR/STTR application support)**

Business Oregon and the Oregon Clinical & Translational Research Institute (OCTRI) are helping Oregon small businesses access federal funding through successful Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications.

Here's what you need to know:

- Phase 0 submissions must be received a minimum of four weeks prior to the sponsoring federal agency's due dates.
- The complete RFA is available [here](#).
- Have questions? Please email [Jonathan Jubera](#).



### **Mobile Apps for Clinical Studies (MACS)**

OCTRI recently launched a new program that allows OHSU PIs to affordably create proof-of-concept mobile apps for clinical studies.

To apply, please download the RFA [here](#), or visit the [OCTRI Biomedical Innovation Program](#) webpage. This program is supported in part by the [Innovation Development and Entrepreneurship Acceleration \(IDEA\)](#)

[Fund](#), co-managed by OHSU Technology Transfer and OHSU Collaborations & Entrepreneurship.

## FEATURED NEWS



### **OHSU and Illumina Honored with Deals of Distinction™ Award**

OHSU Technology Transfer is thrilled to have another licensing deal from OHSU recognized by the [Licensing Executives Society \(U.S.A. and Canada\), Inc.](#) with a Deal of Distinction award. The [LES Deals of Distinction Award](#) is an annual industry sector award program of LES, which aspires to recognize worthy licensing deals and promote creative and innovative solutions to business issues involving contracts. This is the second straight year that OHSU has received this award, and is a testament to the commercial impact of OHSU research and innovation. The deal, negotiated by [Anne Carlson, Ph.D.](#), on behalf of OHSU, exclusively licensed OHSU's rights in three co-owned technologies that were developed over five years under a research collaboration between OHSU and Illumina, and which was led by OHSU's [Andrew Adey, Ph.D.](#)

## FEATURED EVENTS



## **Oregon Bio Digital 2020: Amplifying Diversity of Discovery, Access and Economics**

The [Oregon Bio](#) 2020 annual event will be held virtually on November 17, 18 and 19, offering local researchers and entrepreneurs a forum to share their exciting bioscience research and innovations.

Learn more and register [here](#).

### TECHNOLOGIES AVAILABLE FOR LICENSING

**OHSU #1873-A** - HPa3 Monoclonal Antibody Supernatant from Hybridoma HIC3-2D12 (alpha/delta/gamma/epsilon cell marker)

**OHSU #2700** - A strong mini-promoter for AAV

### NEWLY LICENSED OHSU TECHNOLOGIES

**OHSU #0843** - Mutated ABL Kinase Domains, Inventor: Brian Druker

**OHSU #1771** - Materials from the BioLibrary

**OHSU #2521** - Use of specific stent class for the management of venous stenosis, Inventors: Ramsey Al-Hakim, Khashayar Farsad

**OHSU #2699** - Computational Integration – Reengineering knowledge-intensive work through rebalancing cognitive and computational resources, getting more from people and technology, Inventor: Dave Lawrence

**OHSU #2754** - Delivery and deployment device/mechanism for devices (i.e. stents) with auxetic properties, Inventors: Ramsey Al-Hakim, Khashayar Farsad, John Kaufman

**OHSU #2813** - Agonists of the DNA glycosylase OGG1 - applications in the prevention of metabolic syndrome and treatment of individuals with polymorphic variants of OGG1, Inventors: R. Stephen Lloyd, Amanda McCullough, Irina Minko, Aaron Nilsen

RESEARCHERS IN NEW INDUSTRY-FUNDED  
RESEARCH PROJECTS

[Jacob Estes](#) - Antibody evaluation for HIV cure

[Jeffrey Gold](#), [Matthias Merkel](#), [David Zonies](#) - MURAL usability

[Daniel Marks](#) - Melanocortin antagonists for Cachexia

[Gordon Mills](#) - Efficacy studies of a WEE1 inhibitor

[Amy Moran](#) - Understanding if androgen deprivation therapy with immunotherapy modifies the effector function of tumor-infiltrating T cells

[Renee Ryals](#) - rd10 photoreceptor study

[Thomas Scanlan](#) - Activation of TREM2 multiple sclerosis

[Jeffrey Tyner](#) - Ex Vivo screening of Schrödinger potential cancer drugs

[Xiangshu Xiao](#) - Synthesis and preclinical evaluation of novel CREB

inhibitors

Wassana Yantasee - Cancer and COVID-19 therapeutic testing

UPCOMING EVENTS

NOV 19	2020 OEN Entrepreneurship Awards
NOV 20	The SBIR-STTR Inside-Story Panel Session
DEC 7-11	McKinsey & Company 2020 Virtual Early Stage Investor Conference
DEC 9	How to WIN SBIR/STTR Grants - Half-Day Virtual Presentation

---

Questions? Contact us at [techmgmt@ohsu.edu](mailto:techmgmt@ohsu.edu).

*This monthly publication is created in collaboration with OHSU Technology Transfer, OHSU Collaborations and Entrepreneurship, and the Oregon Clinical and Translational Research Institute.*

---

©2020 OHSU

3181 S.W. Sam Jackson Park Rd. Portland, OR, 97239, US

[Unsubscribe](#)